High Risk of false positive
This profile might be a false positive : due to probable homonyms, we think this profile may contain incorrect informations.
Please read FAQ for more information.

Number of publications published per year by Alsinet, Clara. (Source : PubMed)

Distribution of publications types for Alsinet, Clara. (Source : PubMed)
(a publication can be of different types, so total may exceed publications count)
IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage.
J. Hepatol.
2010;52;4

Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo.
J. Hepatol.
2009;51;4



Pivotal role of mTOR signaling in hepatocellular carcinoma.
Gastroenterology
2008;135;6

Focal gains of VEGFA and molecular classification of hepatocellular carcinoma.
Cancer Res.
2008;68;16
[ See timeline ] [ See all publications ]
means that Alsinet, Clara has 36 papers cited a least 36 times - methodology
Mount Sinai Liver Cancer Program, Mount Sinai School of Medicine, 1425 Madison Avenue, New York, NY 10029, USA.
Due mainly to homonyms, errors are possible and if you detect "false positives" or "false negatives" don't be too frustrated and please contact the webmaster.